Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?-Reference-Cited by-同舟云学术

Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?

Published:2018-11 Issue:6 Volume:17 Page:1067-1071
ISSN:1665-2681
Container-title:Annals of Hepatology
language:en
Short-container-title:Annals of Hepatology

Author:

Lepelley Marion,Allouchery Marion,Long Jérôme,Boucherle Dorothée,Ranchoup Yves,Marc’Hadour François Le,Villier Céline,Sturm Nathalie

Publisher

Elsevier BV

Subject

Hepatology,General Medicine

Reference30 articles.

1. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol;Tandon;Off J Am Soc Clin Oncol,1989

2. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group;Gusterson;J Clin Oncol Off J Am Soc Clin Oncol,1992

3. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer;Chia;Cancer,2007

4. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies;Gennari;Cancer,2005

5. A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapy;Maciá;Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver Pathology Related to Onco-Therapeutic Agents;Surgical Pathology Clinics;2023-09

2. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated malignancies: a pharmacovigilance study based on the FAERS database;Expert Opinion on Drug Safety;2023-04-20

3. Noncirrhotic Portal Hypertension after Trastuzumab Emtansine in HER2-positive Breast Cancer as Determined by Deep Learning–measured Spleen Volume at CT;Radiology;2022-12

4. Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy;Experimental Hematology & Oncology;2022-11-08

5. Stepping forward in antibody-drug conjugate development;Pharmacology & Therapeutics;2022-01